A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F � GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
Read time: 1 mins
Last updated:24th Nov 2011
To ascertain whether the survival of patients randomized to Arm V+G (PROSTVAC plus GM-CSF) or to Arm V (PROSTVAC) is superior to that from patients randomized to Arm P (placebo control).
|Study start date||2011-11-24|